Gemtesa and Parkinson's disease - a phase IV clinical study of FDA data

Summary:

Parkinson's disease is reported as a side effect among people who take Gemtesa (vibegron), especially for people who are female, 50-59 old, also take Rivastigmine, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Parkinson's disease when taking Gemtesa. It is created by eHealthMe based on reports of 2,622 people who have side effects when taking Gemtesa from the FDA, and is updated regularly.

What is Gemtesa?

Gemtesa has active ingredients of vibegron. eHealthMe is studying from 2,648 Gemtesa users. Check the latest studies of Gemtesa.

What is Parkinson's disease?

Parkinson's disease is found to be associated with 1,114 drugs and 1,625 conditions by eHealthMe. Check the latest studies of Parkinson's disease.

On Jul, 14, 2026

2,622 people reported to have side effects when taking Gemtesa.
Among them, 11 people (0.42%) have Parkinson's disease.

Could Gemtesa cause Parkinson's disease?

Among these 11 people:

What is the gender of people who have Parkinson's disease when taking Gemtesa? *

female: 72.73 %
male: 27.27 %

What is the age of people who have Parkinson's disease when taking Gemtesa? *

What are other drugs people take besides Gemtesa? *

What are other side effects people have besides Parkinson's disease? *

Weakness: 5 people, 45.45%
Rib Fracture: 5 people, 45.45%
Bronchiolitis (inflammation of the membranes lining the bronchioles in lungs): 5 people, 45.45%
Embolism (obstruction of an artery, typically by a clot of blood or an air bubble): 5 people, 45.45%
Fall: 5 people, 45.45%
Foot Fracture: 5 people, 45.45%
Herpes Zoster: 5 people, 45.45%
Nasopharyngitis (inflammation of the nasopharynx): 5 people, 45.45%
Limb Injury: 5 people, 45.45%
Sinusitis (inflammation of sinus): 5 people, 45.45%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 5 people, 45.45%
On And Off Phenomenon: 2 people, 18.18%
Iron Deficiency Anaemia: 1 person, 9.09%
Dementia With Lewy Bodies (progressive degenerative disease or syndrome of the brain): 1 person, 9.09%
Dementia (madness): 1 person, 9.09%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Gemtesa and have Parkinson's disease?

- Check whether Parkinson's disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gemtesa:

Gemtesa (2,648 reports)

Browse all side effects of Gemtesa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Parkinson's disease:

Parkinson's disease (1,114 drugs)

Browse all the conditions that are associated with Parkinson's disease:

Parkinson's disease (1,625 conditions)

Related publications that referenced our studies

Woulfe JM, Gray MT, Gray DA, Munoz DG, Middeldorp JM, "Hypothesis: a role for EBV-induced molecular mimicry in Parkinson's disease", Parkinsonism & related disorders, 2014 Jul .
Woulfe JM, Gray MT, Gray DA, Munoz DG, Middeldorp JM, "Hypothesis: a role for EBV-induced molecular mimicry in Parkinson's disease", Parkinsonism & related disorders, 2014 Jul .

How the study uses the data?

The study uses data from the FDA. It is based on vibegron (the active ingredients of Gemtesa) and Gemtesa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.